Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Head and Neck Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1442657

Clinical practice guidelines for the treatment of squamous cell carcinoma of the head and neck: an assessment based on the AGREE II，AGREE-REX tools and the RIGHT checklist

Provisionally accepted
Zhang Yingzhen Zhang Yingzhen Liu Junjie Liu Junjie Liu Shuyu Liu Shuyu *Zhang Ying Zhang Ying *Su Xingzhou Su Xingzhou *Shaohui Huang Shaohui Huang *Duan Weiyi Duan Weiyi *
  • China Medical University, Shenyang, China

The final, formatted version of the article will be published soon.

    The aim of this study was to obtain several published clinical practice guidelines (CPGs) for Head and neck squamous cell carcinoma (HNSCC) and critically assess and compare their quality by using three guideline quality evaluation tools, namely, AGREE Ⅱ, AGREE-REX, and RIGHT, to support the development of future CPGs for HNSCC.Clinical practice guidelines related to the diagnosis and treatment of HNSCC were screened through a comprehensive systematic literature search. Data were extracted from the guidelines which met the inclusion criteria, and two experienced head and neck oncology surgeons were trained to act as independent reviewers. The quality of the retrieved guidelines that met the inclusion and exclusion criteria was evaluated by using the AGREE II, AGREE-REX, and RIGHT tools. Then, the quality of the guidelines that met the criteria was assessed. Finally, conclusions and recommendations were drawn based on the scoring results.A total of eight guidelines met the inclusion criteria. Four guidelines(written by ASCO, NCCN, CCO and KCE) scored > 60% in five or more AGREE II quality domains, two guidelines(written by ASCO and KCE) scored > 60% in all AGREE-REX quality domains, and two guidelines(written by ASCO and KCE) scored > 60% in all quality domains on the RIGHT checklist and were considered "recommendable".The authors recommend consulting the American Society of Clinical Oncology guidelines for HNSCC and suggest that future guideline development groups refer to the guideline evaluation framework for guideline writing to enhance the applicability and effectiveness of clinical practice guidelines.

    Keywords: Squamous cell carcinoma, Head and neck tumor, AGREE II, AGREE-REX, right, Clinical Practice Guidelines

    Received: 02 Jun 2024; Accepted: 28 Nov 2024.

    Copyright: © 2024 Yingzhen, Junjie, Shuyu, Ying, Xingzhou, Huang and Weiyi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Liu Shuyu, China Medical University, Shenyang, China
    Zhang Ying, China Medical University, Shenyang, China
    Su Xingzhou, China Medical University, Shenyang, China
    Shaohui Huang, China Medical University, Shenyang, China
    Duan Weiyi, China Medical University, Shenyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.